Ongoing genomic instability represents a hallmark of multiple myeloma (MM) cells, which manifests largely as whole chromosome- or translocation-based aneuploidy. Importantly, although it supports tumorigenesis, progression and, response to treatment in MM patients, it remains one of the least understood components of malignant transformation in...
-
2015 (v1)PublicationUploaded on: April 11, 2025
-
2015 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2019 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2018 (v1)Publication
No description
Uploaded on: May 12, 2023 -
2016 (v1)Publication
About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction-consolidation program between 2004 and 2013 were retrospectively analyzed. Median age was 47 years. The first induction course included fludarabine (Flu) and high-dose cytarabine (Ara-C) plus idarubicin (Ida), with or without gemtuzumab-ozogamicin (GO) 3...
Uploaded on: April 14, 2023 -
2024 (v1)Publication
CAR(-) CD4(+) T cell lymphopenia is an emerging issue following CAR-T cell therapy. We analyzed the determinants of CD4(+) T cell recovery and a possible association with survival in 31 consecutive patients treated with commercial CAR-T for diffuse large B-cell (DLBCL) or mantle cell lymphoma. Circulating immune subpopulations were...
Uploaded on: July 3, 2024 -
2017 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2022 (v1)Publication
To find prognostic factors for advanced ovarian cancer patients undergoing first-line therapy with carboplatin, paclitaxel and bevacizumab, we investigated the expression of a disintegrin and metalloprotease 17 (ADAM17) in cancer tissues. ADAM17 has been involved in ovarian cancer development, progression and cell resistance to cisplatin....
Uploaded on: May 13, 2023 -
2018 (v1)Publication
Genomic instability plays a pathological role in various malignancies, including acute myeloid leukemia, and thus represents potential therapeutic target. Recent studies demonstrate that SIRT6, a NAD+-dependent nuclear deacetylase, functions as genome-guardian by preserving DNA integrity in different tumor cells. Here, we demonstrate that also...
Uploaded on: March 27, 2023